Popular Articles

Likelihood Of Survival May Be Improving For Extremely Preterm Infants
Infants born extremely preterm are surviving at a high rate, with about 70 percent of infants born alive between 22 and 26 weeks of gestation in Sweden surviving at least one year, with high rates of interventions being used to improve survival, according to a study in the June 3 issue of JAMA, a theme issue on child and adolescent health.
generic viagra online
Blue Dogs' Bargain Blasted As Centrists' Role Questioned
Kaiser Health News reports that an agreement by House Democrats with fiscally conservative Blue Dog Democrats has a cadre of detractors, including "state officials worried about increased Medicaid costs and liberal lawmakers upset about a proposed reduction in subsidies for low-income families to buy insurance."
News of the day
Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma
Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.
Endocrinology

AIBN And US Researchers Join Forces, Australia

A UQ institute has joined forces with a leading American university to work on research to change the way we live. The University of Queensland"s Australian Institute for Bioengineering and Nanotechnology and the Nanobiotechnology Center (NBTC) at Cornell University in the United States are working together to develop new products and techniques that will promote new medicines, develop the next generation of biofuels and improve human health and quality of life. By signing a Memorandum of Understanding, both organisations stand to enhance their mutual interests in biomolecular devices and analysis, cell and tissue engineering, cell surface interaction and nanomaterials. AIBN Director, Professor Peter Gray said that together AIBN and NBTC would increase the pace of discovery and development of new products and processes. "AIBN and NBTC are both highly interdisciplinary research environments and the combination of biology, nanotechnology and engineering in these organisations has the potential to change our lives," Professor Gray said. "For example, the scientific breakthroughs which are occurring in the fields of stem cells and tissue regeneration are opening up many new opportunities for treating disease but for the potential to be realised, we need to learn how to target the new treatments to just the right part of the body, and how to grow very complex cells in a controlled fashion. "This MOU will establish new partnerships, enable joint funding opportunities and promote the sharing of ideas, techniques and skills, as well as develop new research directions. "I look forward to working with NBCT Director Professor Harold Craighead to grow this relationship in the future," he said. "The NBTC and AIBN have allied missions and I believe that by combining our expertise and efforts we can work even more effectively to address important issues in our society," Professor Craighead said. "Our research into single molecule biochemistry using nanostructured devices, is suggesting new approaches for early diagnosis of disease and delivery of individually tailored treatments," he said. Professor Craighead is currently visiting the Institute as part of the AIBN Symposium, an important fixture on the AIBN Calendar where staff and students gather to discuss some of the many research projects being undertaken. The University of Queensland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):